Pharmaceuticals

Macugen Market Revenue Projected To Hit $2.37 Billion By 2030 With 11.8% CAGR

May 5, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Macugen Market Projected To Reach By 2030?

The historical period’s growth can be attributed to an increased occurrence of age-related macular degeneration, a greater detection rate for diabetic eye conditions, the proliferation of specialized ophthalmology clinics, the prompt uptake of anti-VEGF treatments, and advancements in retinal imaging technologies.

The projected growth during the forecast period is propelled by factors such as a heightened demand for prolonged-release ocular formulations, increasing financial commitments to retinal disease research, the rising acceptance of customized ophthalmic treatments, the expansion of eye care provisions for the aging demographic, and an intensified focus on minimizing injection frequency.

Key trends anticipated in the forecast period encompass the expanded utilization of targeted anti-VEGF therapies, a growing adoption of intravitreal injection treatments, an increasing emphasis on therapies aimed at preserving vision, the broadening of retinal disease management protocols, and a reinforced focus on the long-term effectiveness of treatments.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20440&type=smp

Which Important Drivers Are Guiding The Macugen Market Growth?

The increasing occurrence of age-related macular degeneration (AMD) is anticipated to propel the growth of the macugen market moving forward. Age-related macular degeneration (AMD) is a progressive eye condition that impacts the macula, which is the central part of the retina responsible for clear and detailed vision. The rising prevalence of age-related macular degeneration (AMD) is linked to an aging global population, extended life expectancy, and lifestyle factors such as smoking, poor diet, and prolonged exposure to ultraviolet (UV) light. Macugen is beneficial for age-related macular degeneration (AMD) as it works by inhibiting vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth and leakage in the retina, and thereby helping to preserve vision and slow disease progression. For instance, in May 2023, according to an article published by the National Center for Biotechnology Information, a US-based National Institutes of Health government agency, approximately 288 million individuals are projected to be affected by age-related macular degeneration (AMD) by 2040. Therefore, the growing prevalence of age-related macular degeneration (AMD) is driving the expansion of the macugen market.

What Are The Main Segments Within The Macugen Market Segment Structure?

The macugen market covered in this report is segmented –

1) By Indication: Wet AMD(Age-Related Macular Degeneration (AMD)), Diabetic Macular Edema

2) By Formulation: Intravitreal Injection, Extended-Release Formulations

3) By Distribution Channel: Hospitals And Clinics, Retail And Specialty Pharmacies

4) By End User: Adult Patients, Geriatric Patients

Which Trends Are Guiding The Direction Of The Macugen Market?

A significant trend emerging within the macugen market is the progression of gene therapy. This therapeutic approach entails inserting genetic material into patient cells to combat or avert illness, particularly focusing on age-related macular degeneration (AMD). As an illustration, during 2023, Regenxbio, a biotechnology firm based in the U.S., unveiled RGX-314, a gene therapy solution crafted to introduce a gene responsible for an anti-VEGF protein straight into the eye. This cutting-edge treatment seeks to deliver enduring benefits by lessening the requirement for repeated injections. Distinctive attributes of RGX-314 encompass its potential for a singular dose, which stands to considerably enhance patient adherence, and its capacity to address the fundamental etiologies of AMD instead of merely alleviating symptoms. Such progress places companies advantageously within the continually changing domain of ocular treatments.

Who Are The Companies Participating In The Macugen Market?

Major companies operating in the macugen market are Bausch + Lomb Inc

Get The Full Macugen Market Report:

https://www.thebusinessresearchcompany.com/report/macugen-global-market-report

Where Is The Macugen Market Primarily Concentrated By Region?

North America was the largest region in the macugen market in 2025. The regions covered in the macugen market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Macugen Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/macugen-global-market-report

Browse Through More Reports Similar to the Global Macugen Market 2026, By The Business Research Company

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

M Commerce Payment Market Report 2026

https://www.thebusinessresearchcompany.com/report/m-commerce-payment-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795